Speaker illustration

Doctor Inna Thalmann

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology

Inna joined the Health Economics Research Centre at the Nuffield Department of Population Health, University of Oxford, in October 2017 as a PhD student. Her research investigates trends and determinants of medication use for the secondary prevention of cardiovascular disease in the UK, using NHS Scotland and UK Biobank data. Her research at Oxford is funded by a Medical Research Council UK (MRC) and Nuffield Department of Population Health (NDPH) scholarship, and a British Heart Foundation Centre of Research Excellence (BHF CRE) Pump Priming grant.

Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland

Event: ESC Congress 2022

Topic: Secondary Prevention

Session: Secondary prevention 2


Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009-2017

Event: ESC Congress 2020

Topic: Public Health

Session: Cardiovascular Disease Prevention and Treatment: What Drives Change?


ESC 365 is supported by

logo Novo Nordisk